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Vascular endothelial dysfunction has been demonstrated in metabolic syndrome (MS). Chronic administration of rosiglitazone
ameliorates endothelial dysfunction through PPARγ-mediated metabolic improvements. Recently, studies suggested that single
dose of rosiglitazone also has direct vascular eﬀects, but the mechanisms remain uncertain. Here we established a diet-induced
rat model of MS. The impaired vasorelaxation in MS rats was improved by incubating arteries with rosiglitazone for one hour.
Importantly, this eﬀect was blocked by either inhibition of PPARγ or PPARδ. In cultured endothelial cells, acute treatment with
rosiglitazone increased the phosphorylation of Akt and eNOS and the production of NO. These eﬀects were also abolished by
inhibition of PPARγ,P P A R δ, or PI3K. In conclusion, rosiglitazone improved endothelial function through both PPARγ-a n d
PPARδ-mediated phosphorylation of Akt and eNOS, which might help to reconsider the complex eﬀects and clinical applications
of rosiglitazone.
1.Introduction
Metabolic syndrome is characterized by a combination of
metabolic disorders that increase the risk of developing
cardiovascular disease. Vascular endothelial dysfunction has
been demonstrated in metabolic syndrome with and without
hypertension or diabetes [1–3]. Thiazolidinediones (TZDs),
which are a class of powerful insulin sensitizers, are ideal
candidates for the early treatment of metabolic syndrome.
There is also a growing body of in vivo evidence suggesting
that TZDs improve endothelial function [4–7] and have a
small reducing eﬀect on blood pressure [8, 9]. The vascular
protective eﬀects might be a consequence of the metabolic
changes that are mainly mediated by the transcription factor,
peroxisome-proliferator-activated receptor (PPAR) γ [6, 8,
10, 11]. However, studies suggest that a single dose of
rosiglitazone has a direct eﬀect on endothelial function,
which is independent of the metabolic improvement [12].
These studies imply that the short-term application of
rosiglitazone might have endothelial beneﬁts without any
side eﬀects, although the long-term intake of rosiglitazone
is associated with an increased risk of heart failure. However,
the mechanism by which rosiglitazone improves endothelial
function remains uncertain. Although PPARγ in endothelial
cells (ECs) is involved in the regulation of nitric oxide (NO)
[13], the production of reactive oxygen species [14], and
the synthesis of endothelin receptor [15], rosiglitazone also
has PPARγ-independent eﬀects in isolated vasculatures and
cultured ECs [16].
Unlike PPARγ, the most ubiquitously expressed PPAR
isoform, PPARδ, has been less studied in the vasculature.
Previous studies have mainly focused on the metabolic
role of PPARδ in tissues like skeletal muscle and adipose
tissue. In recent years, the role of PPARδ in the vasculature
has attracted more attention. PPARδ in endothelial cells
plays a role in the regulation of oxidative injury, inﬂam-
mation, blood coagulation, cell proliferation, and apoptosis
[17, 18]. One recent study revealed that PPARδ agonists2 PPAR Research
acutely cause vasodilatation, which is partially dependent
on endothelial NO synthase (eNOS) activation through
the Akt pathway [19]. PPARδ activation in ECs produces
an acute transcription-independent regulation of eNOS
phosphorylation. Several studies indicate that rosiglitazone
may enhance eNOS phosphorylation and vasorelaxation
independent of genomic transcriptional regulation [16, 20].
Therefore, it is hypothesized that, in addition to PPARγ
activation, PPARδ activation might also play an important
role in the vascular protective eﬀects of rosiglitazone.
The present study was designed to conﬁrm the acute
beneﬁcialeﬀectsofrosiglitazone on endothelial functionand
to explore the mechanism by which rosiglitazone directly
aﬀects the endothelium in isolated arteries of a rat model of
metabolic syndrome.
2.MaterialsandMethods
2.1. Animals. Male Wistar rats 6 to 8 weeks of age were
obtained from an in-house breeding colony and randomized
into two groups, receiving either a standard chow diet
(Chow) or a high-fat diet (HFD) for32 weeks [21].TheHFD
supplied 59% of the calories as fat and 20% of the calories
as carbohydrates in the form of cornstarch and sucrose
(2:1w/w).TheChowdietprovided10%ofthecaloriesasfat
and 65% as carbohydrates. The animals were housed under
controlled temperatures (21–23◦C) with a 12/12h light-dark
cycle (lights on from 06:00 to 18:00). All animals had free
access to water and food. Systolic blood pressure (tail-cuﬀ
method) and body weight were measured weekly. At the end
of 32 weeks, rats were sacriﬁced after fasting for 12h, and
the second-order mesenteric arteries were used for isometric
force measurement. Blood was collected from the carotid
arteries, and the plasma levels of triglycerides, glucose, and
insulin were measured using commercially available assay
kits (Applygen Technologies Inc., Beijing, China). All of the
experimental procedures were performed in accordance with
protocols approved by the Institutional Animal Care and
Research Advisory Committee.
2.2. Isometric Tension Measurement. Second-order mesen-
teric arteries were dissected and cut into 3mm rings in cold
Krebs solution containing the following (in mmol/L): NaCl
119, NaHCO3 25, glucose 11.1, KCl 4.7, KH2PO4 1.2, MgSO4
1.2, and CaCl2 2.5, with pH 7.4. Tissues were cultured
for 1h in prewarmed Dulbecco’s modiﬁed Eagle medium
(DMEM)supplementedwith10%FetalBovineSerum(FBS)
and 1% antibiotics. Rosiglitazone (20μmol/L), GW9662
(PPARγ antagonist,1μmol/L),GSK0660(PPARδ antagonist,
1μmol/L), GW6471 (PPARα antagonist, 1μmol/L), and
the eNOS inhibitor, NG-nitro-L-arginine methyl ester (L-
NAME, 100μmol/L) were added as indicated in separate
experiments. Tension changes of the cultured arteries were
recorded as described previously [22]. Brieﬂy, the arterial
segments were suspended by two stainless steel wires in a
four-chamber wire myograph (model 610M; Danish Myo
Technology, Aarhus, Denmark) and maintained at 37◦Ci n
Krebs solution gassed with 95% O2 and 5% CO2.A f t e r
a 30min equilibration, the rings were ﬁrst contracted by
10μmol/L phenylephrine (PE) and then relaxed by 1μmol/L
acetylcholine(ACh).Arterieswithrelaxationsover80%were
regarded as having an intact endothelium. After several
washes, a sustained contraction was induced by adding
10μmol/L PE to the rings, and cumulative concentration
r e l a x a t i o n su s i n gA C h( 1 0 −9–10−5 mol/L) and nitroglycerin
(10−9–10−5 mol/L) were performed.
2.3. Cell Culture. Porcine iliac artery endothelial cells
(PIECs) were obtained from the Institute of Biochemistry
and Cell Biology (Chinese Academy of Sciences, Shanghai,
China). PIECs were grown in DMEM supplemented with
10% FBS and 1% antibiotics. Cultures were maintained at
37◦C in a humidiﬁed atmosphere of 95% air/5% CO2.C e l l s
weremadequiescentbyincubationof90%conﬂuentcellcul-
tures in serum-free DMEM and incubated with rosiglitazone
(2μmol/L) for 1h in the presence or absence of GW9662
(1μmol/L), GSK0660 (1μmol/L), GW6471 (1μmol/L), or
the PI3K inhibitor, LY294002 (1μmol/L).
2.4. Immunoblotting. Immunoblotting of phosphorylated
eNOS (Ser-1177), total eNOS, phosphorylated Akt (Ser-
473), total Akt, and GAPDH in PIECs were performed
using standard techniques as described previously [22, 23].
GAPDH was used as a loading control. All of the primary
antibodies were purchased from Santa Cruz Biotechnology
(Santa Cruz, Calif, USA). Cells were lysed in a high-salt
extraction buﬀer (0.5mol/L Tris, 1% NP-40, 1% Triton X-
100, 1g/L sodium dodecyl sulfate, 1.5mol/L NaCl, 0.2mol/L
EDTA, and 0.01mol/L EGTA) plus 0.2mmol/L protease
inhibitor and placed at −20◦C for 20 minutes. Cells were
centrifuged at 12,000×ga t4 ◦Cf o r2 0m i n u t e st or e m o v e
insoluble materials. Protein concentrations were determined
using a DC protein assay kit (Bio-Rad, Hercules, Calif,
USA). Fifty micrograms of lysates were separated by SDS-
PAGE, transferred to polyvinylidene diﬂuoride membranes
and blocked with 5% nonfat milk in PBS at 37◦Cf o r
4h. The proteins were probed with primary antibodies in
0.1% Tween-20/PBS at 4◦C overnight. After incubation with
the appropriate secondary antibodies at 37◦C for 2h, the
proteins were detected by enhanced chemiluminescence and
quantiﬁed using a Gel Doc 2000 Imager (Bio-Rad, Calif,
USA).
2.5. Evaluation of NO Production. NO levels in PIECs were
assessed using DAF-2 DA (4,5-diaminoﬂuorescein) as de-
scribed previously [22]. Cells grown on glass slides were
incubated with rosiglitazone or vehicle for 1h in fresh
DMEM in the presence or absence of indicated antagonists.
Then cells were washed and loaded with 2μmol/L DAF-2DA
(Sigma-Aldrich) in the dark for 30min at 37◦Ci nK r e b s
solution (pH 7.4). Cells were washed three times with fresh
Krebs solution. To quantitate the DAF ﬂuorescence, the cells
were observed under an inverted ﬂuorescence microscope
(Nikon TE2000, Nikon, Japan). Images were acquired and
the ﬂuorescence intensity was analyzed using NIS-Elements
3.0 software (Nikon).PPAR Research 3
2.6. Statistical Analysis. Data are presented as the means ±
SEM. of n experiments. The half maximal eﬀective agonist
concentration (EC50) and maximum response (Emax)w e r e
calculated from individual agonist concentration-response
curves using GraphPad Prism 3.0 (GraphPad Software, San
Diego, Calif, USA). Statistical diﬀerences between groups
were assessed using Student’s t-test or one-way analysis of
variance (ANOVA) with Bonferroni’s multiple comparison
post hoc tests as appropriate. Two-sided P values <0.05 were
considered statistically signiﬁcant.
3. Results
3.1. The HFD-Induced Rat Model of Metabolic Syndrome.
Long-term HFD administration produced features of
metabolicsyndromeinWistar-Kyoto(WKY)rats.Compared
to control rats on a normal chow diet, rats on HFD had
a more rapid and extreme weight gain. At the age of 32
weeks, the body weight of rats on HFD was 30% greater than
c o n t r o lr a t s( F i g u r e1(a)). More importantly, the visceral
fat component in HFD-fed rats was nearly 100% greater
than controls (Figure 1(b)). As expected, HFD rats also had
markedly higher fasting plasma levels of insulin, glucose, and
triglycerides (Figures 1(c)–1(e)). Furthermore, the tail-cuﬀ
blood pressure of HFD-fed rats was signiﬁcantly elevated
compared to controls (Figure 1(f)).
3.2. Rosiglitazone Restored the Endothelial Dysfunction in
the Rat Model of Metabolic Syndrome through Both PPARγ
and PPARδ Activation. To exclude the multiple metabolic
eﬀects in vivo, vasorelaxation was examined in isolated
mesenteric arteries of rats with or without HFD-induced
metabolic syndrome. Compared to control rats, the ACh-
induced endothelium-dependent vasorelaxation in HFD-
fed rats was signiﬁcantly impaired (Figure 2(a);H F D :
Emax = 64.94 ± 4.18%, Chow: Emax = 89.53 ± 4.19%,
P<0.01), but the nitroglycerine-induced endothelium-
independent vasorelaxation was similar between the two
groups (Figure 2(b);H F D :E max = 88.01 ± 3.98%, Chow:
Emax = 91.32 ± 3.56%, P>0.05). Pretreatment with
rosiglitazone for 1h markedly restored the endothelium-
dependentvasorelaxationinHFD-fedrats(Figure2(c);RGZ:
Emax = 83.66 ± 4.21%, Control: Emax = 64.94 ± 4.18%,
P<0.05). In the presence of the NOS inhibitor L-NAME,
the ACh-induced vasorelaxation was almost completely
abolished, and there was no diﬀerence between arteries
with and without rosiglitazone pretreatment (Figure 2(c)).
Because rosiglitazone is a partial agonist for PPARγ,w e
further observed an eﬀect of rosiglitazone in the presence of
antagonists for the three PPAR isoforms. The PPARγ antago-
nist GW9662 signiﬁcantly blocked the action of rosiglitazone
(Figure 2(d); RGZ + GW9662: Emax = 69.31 ± 3.10%, RGZ:
Emax = 83.66 ± 4.21%, P<0.05). Surprisingly, a signiﬁcant
block of the action of rosiglitazone was also observed in
arteries pretreated with the PPARδ antagonist GSK0660
(Figure 2(d); RGZ + GSK0660: Emax = 70.91 ± 3.45%, RGZ:
Emax = 83.66 ± 4.21%, P<0.0 5 ) .H o w e v e r ,n oe ﬀect of
the PPARα antagonist GW6471 was detected (Figure 2(d)).
We further studied the vascular eﬀects of rosiglitazone in
the presence of the combination of GSK0660 and GW9662
(Figure 2(d)). It showed that the combination of GSK0660
and GW9662 had an additive inhibitory eﬀect on vasodila-
tion, which completely abolished the rosiglitazone-induced
eﬀect. It suggests that rosiglitazone may exert its endothelial
protective role through complementary activation of PPARγ
and PPARδ.
3.3. Rosiglitazone Promoted Akt and eNOS Phosphorylation
through the Activation of PPARγ and PPARδ. To explore the
molecularmechanisminvolvedinrosiglitazoneactiononthe
vascular endothelium, the porcine vascular endothelial cell
linewasculturedandtreatedwithrosiglitazonewithorwith-
out PPAR antagonists. Rosiglitazone signiﬁcantly increased
the phosphorylation of eNOS and Akt but had no eﬀects on
the expression of total eNOS and total Akt (Figures 3(a)–
3(c)). Both antagonists for PPARγ and PPARδ, GW9662
and GSK0660, signiﬁcantly attenuated the rosiglitazone-
induced phosphorylation of Akt and eNOS (Figures 3(a)–
3(c)).However,thePPARαantagonistGW6471didnotaﬀect
the rosiglitazone-induced phosphorylation of eNOS or Akt
(Figures 3(a)–3(c)).
3.4. Rosiglitazone Increased NO Production through the
PPARγ- and PPARδ-Dependent PI3K/Akt Pathway. NO pro-
duction in endothelial cells was determined using the DAF-2
ﬂuorescence assay. Rosiglitazone signiﬁcantly increased NO
production in endothelial cells (Figures 4(a) and 4(b)). The
PPARδ antagonist GSK0660 and PPARγ antagonist GW9662
both markedly attenuated the rosiglitazone-induced NO
production (Figures 4(a) and 4(b)). However, the PPARα
antagonist GW6471 had no eﬀect on the NO production
in endothelial cells (Figures 4(a) and 4(b)). To deter-
mine whether the PI3K/Akt pathway was required for the
rosiglitazone eﬀect, we stimulated cells with rosiglitazone
in the presence of the PI3K inhibitor LY294002 and found
that rosiglitazone-induced NO production was almost com-
pletely blocked (Figures 4(a) and 4(b)).
4. Discussion
The present study demonstrated that rosiglitazone improved
endothelial function in isolated arteries from a rat model
of metabolic syndrome through both PPARγ-a n dP P A R δ-
mediated phosphorylation of Akt and eNOS. The short-
term and direct endothelial eﬀects of rosiglitazone and the
involved new target, PPARδ, might lead to a reconsideration
of the complex eﬀects and clinical applications of rosiglita-
zone.
Metabolic syndrome is always associated with vascular
dysfunction and the common characteristic of endothe-
lium impairment, which is the earliest known marker of
atherosclerosis [1, 24, 25]. Our previous study established
the diet-induced rat model of metabolic syndrome and
observed multiple metabolic disorders, including central
obesity, insulin resistance, dyslipidemia, and hypertension4 PPAR Research
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Figure 1: Biometric characteristics of rats on normal chow diet (Chow, n = 10) and high-fat diet (HFD, n = 12) for 32 weeks. (a) Body
weight; (b) Visceral fat percentage; (c) Fasting plasma insulin level; (d) Fasting plasma glucose; (e) Fasting plasma triglycerides; (f) Systolic
blood pressure by tail-cuﬀ method. Data are means ± SEM ∗P<0.05, ∗∗P<0.01 compared to Chow.
[21]. The current study further found that endothelium-
dependent relaxation was impaired, but the endothelium-
independentrelaxationwasnormalinthemesentericarteries
of these rats.
A large number of in vivo studies have proven that
rosiglitazone has various beneﬁcial eﬀects on metabolism,
vascular function, and blood pressure in humans and
animals [10, 11, 20]. Although the improvement of insulin
sensitivity, glucose, lipids, and adiponectin could contribute
to the changes in vascular function, studies in healthy
humans and transgenic hypertensive animals have also
shown that rosiglitazone might exhibit direct vascular eﬀects
that are independent of these metabolic actions [12, 20].
Our study conﬁrmed the direct eﬀects of rosiglitazone on the
endothelium using short-term stimulation in isolated vessels
and cultured endothelial cells.
TZDs, such as rosiglitazone, ameliorate endothelial
dysfunction by stimulating NO generation through an
upregulation of eNOS expression and eNOS-Ser1177 phos-
phorylation in animal models and cultured endothelial
cells [16, 26, 27]. Our study also observed an increase
in NO production and eNOS-Ser1177 phosphorylation in
endothelial cells treated with rosiglitazone. However, eNOS
expression was not changed by rosiglitazone. In previous
studies, cells stimulated with rosiglitazone or troglitazone
for up to 24h showed changes in genomic expression
[16, 26]. In the current study, cells were cultured with
rosiglitazone for only 1h. Genomic changes were not likelyPPAR Research 5
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Figure 2: Rosiglitazone attenuated the vascular dysfunction in rats on HFD through PPARγ and PPARδ activation. (a, b) Acetylcholine-
(a) and nitroglycerin- (b) induced relaxation in isolated mesenteric arteries from rats on normal chow diet and HFD diet. (c, d) Eﬀects of
rosiglitazone pretreatment on the Acetylcholine-induced vasorelaxation in rats on HFD in the absence or presence of L-NAME (c) or PPAR
antagonists (d). RGZ: rosiglitazone; L-NAME: eNOS inhibitor; GSK0660: PPARδ antagonist; GW9662: PPARγ antagonist; GW6471: PPARα
antagonist. Data are means ± s.e.m. from 6 separate experiments. ∗P<0.05, ∗∗P<0.01 between the Emax of indicated groups.
to occur in such a short period. Therefore, an acute non-
transcriptionaleﬀectofrosiglitazoneprobablyoccurred.The
phosphorylation of eNOS might involve PI3K/Akt pathway
[28, 29], which could be activated by rosiglitazone [30]. In
the current study, the phosphorylation of Akt and eNOS
was simultaneously increased by rosiglitazone, and the PI3K
inhibitor LY294002 abolished rosiglitazone-induced NO
production. These results strongly support that the short-
term endothelial beneﬁts of rosiglitazone were mediated by
the phosphorylation of Akt/eNOS. This acute nongenomic
eﬀect of rosiglitazone is consistent with the study of Boyle
et al. who found an increase in eNOS phosphorylation and
no change in total eNOS expression in cells incubated with
rosiglitazone for 1-2h [31].
Studies of the role of PPARγ in the direct endothelial
eﬀects of TZDs have shown inconsistent results. In human
umbilical vein endothelial cells (HUVECs), rosiglitazone-
stimulated NO production and eNOS phosphorylation are6 PPAR Research
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Figure 3: Rosiglitazone increased the phosphorylation of Akt and eNOS through PPARγ and PPARδ activation in cultured endothelial cells.
(a) Representative immunoblots of phosphorylated and total eNOS and Akt in cells treated with rosiglitazone (RGZ) in the presence or
absence of PPAR antagonists. GAPDH was used as loading control. (b, c) Summary densitometry data showing the ratio of phospho-eNOS
(p-eNOS) relative to total eNOS (eNOS) and phospho-Akt (p-Akt) relative to total Akt (Akt). Data are means ± SEM from 3 separate
experiments. ∗P<0.05, ∗∗P<0.01 versus Control. #P<0.05 versus RGZ.
completely inhibited by the PPARγ antagonist GW9662
[26]. In human aortic endothelial cells, however, GW9662
has no eﬀect on the rosiglitazone-induced acute activation
of eNOS phosphorylation [31]. In the current study, the
inhibition of PPARγ with GW9662 partially abrogated
rosiglitazone-induced NO production and Akt and eNOS
phosphorylation. Although the principal function of PPARγ,
the known target of TZDs, is genomic regulation, it has
been recently reported that PPARγ physically interacts with
proteinkinases,whichresultsinanacuteactivitymodulation
of these enzymes [32]. Our results support that, in addition
to the chronic genomic regulation, PPARγ also participates
in the acute phosphorylation of Akt and eNOS.
Most importantly, the present study revealed for the ﬁrst
time that endothelial PPARδ was activated by rosiglitazone
and participated in the acute eﬀects of rosiglitazone on
endothelium-dependent vasodilation. Previous studies have
found that rosiglitazone, a PPARγ ligand, also shows various
PPARγ-independent vascular eﬀects. Therefore, PPARδ may
be at least partially responsible for the PPARγ-independent
eﬀects of rosiglitazone. Actually, several studies have sug-
gested that rosiglitazone might have PPARδ-dependent
eﬀects in some types of cells and tissues. Rosiglitazone
inhibits lipopolysaccharide target genes in PPARγ-deﬁcient
macrophages, at least in part by activating PPARδ [33]. In
rat synovial ﬁbroblasts, IL-1 receptor antagonist production
induced by rosiglitazone is abolished by dominant-negative
PPARδ and is reproduced by the PPARδ agonist GW-501516
[34]. In rosiglitazone-treated obese patients with type 2
diabetes, improved insulin sensitivity and skeletal muscle
oxidative enzyme activity is associated with an upregulation
of PPARδ expression [35]. In the current study, we revealed
that rosiglitazone exhibited direct vasodilator eﬀects partly
through PPARδ activation in endothelial cells. PreviousPPAR Research 7
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Figure 4: Rosiglitazone increased NO production in cultured endothelial cells through PPARγ-a n dP P A R δ-dependent PI3K/Akt pathway.
(a) Representative images of DAF-2 DA-loaded cells treated with rosiglitazone (RGZ) in the presence or absence of PPAR antagonists or
LY294002,thePI3Kinhibitor.(b)SummarydataoftheDAF-2ﬂuorescence.Dataaremeans ±SEMfrom4separateexperiments. ∗∗P<0.01
versus Control. ##P<0.01 versus RGZ.
studies have demonstrated that PPARδ plays a direct role in
various basic vascular processes, such as apoptosis, survival,
angiogenesis, and inﬂammation [36–38]. Particularly, one
recent study reported that PPARδ agonists, L165041 and
GW0742, acutely cause vasodilatation that is dependent on
endothelial-derived NO, and the PPARδ-mediated endothe-
lial NOS activation is related to the PI3K-Akt-eNOS pathway
[19] .T h er o l eo fP P A R δ in the acute nongenomic regulation
of eNOS is consistent with the ﬁndings of our current
study.
In this study we only showed the vascular eﬀects of
rosiglitazone in MS rats with impaired endothelial function
but not in rats with normal endothelial function. In several
previousstudies,rosiglitazonewasshowntohavevasodilator
eﬀects in normal animals and humans. Tian et al. demon-
strated that rosiglitazone attenuated endothelin-1-induced
vasoconstriction through the upregulation of endothelin B
receptor and NO production in normal mouse aortas [15].
Hsieh and Hong reported that chronic rosiglitazone treat-
ment augmented vascular responsiveness to acetylcholine
and lowered blood pressure in normal male rats [39].
Walcher et al. showed a rapid eﬀect of single dose rosigli-
tazone treatment on ﬂow-mediated endothelium-dependent
vasodilatation in healthy men [12]. These studies underscore
the direct relaxation eﬀects of rosiglitazone in normal sub-
jects. However, it needs to clarify whether rosiglitazone can
cause acute endothelium-dependent vasorelaxation through
both PPARδ and PPARγ activation in normal animals.8 PPAR Research
In conclusion, the main ﬁnding of the present study is
that, in addition to acting as a PPARγ agonist, rosiglitazone
also activates PPARδ in endothelial cells. Both PPARγ and
PPARδ contribute to the vasodilator eﬀect of rosiglitazone
through an increase in NO production from the phos-
phorylation of Akt and eNOS. The possible new target of
rosiglitazone, PPARδ, may promote an understanding of the
wide range of properties of TZDs. More importantly, this
study highlights the direct and short-term vascular eﬀects
of rosiglitazone in addition to the generally known chronic
metabolic eﬀects, and these vascular eﬀects might provide a
much safer and new clinical application of rosiglitazone.
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